Second tumors in children with hematological malignancies

Author:

Susuleva N. A.1ORCID,Valiev T. T.1ORCID,Martynova N. S.1,Mikhaylova S. N.2ORCID

Affiliation:

1. Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Abstract

Background. Hemoblastoses treatment success in children made it possible to cure the vast majority of patients. The follow-up period exceeds tens of years, during which the problem of second tumors (ST) becomes urgent.  The objective of the study was to characterize ST in patients who underwent a malignant tumor of hematopoietic and lymphoid tissues at the age of 0 to 18 years.Materials and methods. The study included 64 patients with ST development in the period from 1 to 38 years.Results. Most frequently ST developed after treatment of Hodgkin's lymphoma (45.3 %) and acute lymphoblastic leukemia (35.9 %), supported by high cumulative doses of alkylating agents and radiation therapy. Among STs, in 35.9 % of cases, thyroid cancer was diagnosed, in 10.9 % - acute leukemia, in 9.4 % - tumors of the central nervous system.  The results of ST treatment are significantly worse than those of primary tumors. Thus, of 64 patients with ST, 46 (71.9 %) are alive, death from ST progression was noted in 18 (28.1 %) cases.Conclusion. Improvement of modern treatment protocols aimed at reducing the indications for radiation therapy and cumulative doses of alkylating agents, along with the development of effective follow-up programs for children cured of hematological malignancies, will probably help reduce the ST incidence.

Publisher

Publishing House ABV Press

Subject

Oncology,Hematology

Reference35 articles.

1. SEER Cancer Statistics Review 19752010. 2013. Available at: http://seer.cancer.gov/csr/1975_2010/browse_csr.php?section=28&page=sect_28_table.08.html. Accessed 10.01.2013.

2. National Cancer Institute. Late Effects of Treatment for Childhood Cancer: Subsequent Neoplasms. 2013. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/lateeffects/HealthProfessional/page2#Reference2.18. Accessed 10.01.2013.

3. Meadows A., Friedman D., Neglia J. et al. Second neoplasms in survivors of childhood cancer: findings from the childhood cancer survivor study cohort. J Clin Oncol 2009;27(14):2356-62. DOI: 10.1200/JCO.2008.21.1920.

4. Friedman D.L., Whitton J., Leisenring W. et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102(14):1083- 95. DOI: 10.1093/jnci/djq238.

5. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer. cancer.gov) SEER*Stat. Research Data(1973-2010), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. 2013.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3